Efficacy and Safety of memanTine in the Treatment Of Frequently symPtomatic Atrial Premature Beats
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 256 participants.
Also called NCT06501638
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 256 participants
- Sponsor
- Registry
-
NCT06501638
-
- Other papers using this trial's data
- Memantine for Premature Atrial Contractions: A Phase 2 Randomized Clinical Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT06501638. Randomized; quadruple masking; primary purpose treatment. Start 2024-08-29 (actual); primary completion 2025-03-21 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of memanTine in the Treatment Of Frequently symPtomatic Atrial Premature Beats
- Acronym
- STOP-AP
- Condition
- Atrial Premature Beats, Contractions, or Systoles
- Intervention (Drug)
- Memantine Hydrochloride 10 MG
- Intervention (Drug)
- Placebo
- Lead sponsor
- Shanghai East Hospital
Record details
- Record id
cardio:ct-nct06501638- Content hash
c60c533c43454753af75e41a59a1cefa7dcb28e49c83b7c3df2a3f3f72ba2f86